Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,582 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Juvenile-Onset Clear all
Recruiting Phase 2 Interventional

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

NCT05414409
View directory record Official record
Conditions
Type 1 Diabetes, Obesity
Interventions
Metformin
Drug
Lead sponsor
Heba M. Ismail
Other
Eligibility
11 Years to 18 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acceptability of Self-Led Mindfulness-Based Intervention

NCT05115175
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Mindfulness-Based Stress Reduction
Behavioral
Lead sponsor
University of Nevada, Reno
Other
Eligibility
13 Years to 19 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes

NCT00645840
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Anakinra
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Not applicable Interventional Results available

Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes

NCT02734667
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM at diagnosis of T1D
Device
Lead sponsor
Korey Hood
Other
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 23, 2026, 7:52 AM EDT
Not yet recruiting Not applicable Interventional

Feasibility Study of a Continuous Glucose-Ketone Monitoring Device in People With Type 1 Diabetes

NCT06977633
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Temporary Insulin Suspension, Glucose and ketone sensor
Behavioral · Device
Lead sponsor
Mahla Poudineh
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Umbilical Cord Blood Infusion to Treat Type 1 Diabetes

NCT00305344
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Autologous Umbilical Cord Blood Transfusion, Cord blood
Procedure · Biological
Lead sponsor
University of Florida
Other
Eligibility
1 Year and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 23, 2026, 7:52 AM EDT
Active, not recruiting No phase listed Observational

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

NCT04595474
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes, Cirrhosis, Liver
Interventions
Transient Elastography
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Phase 4 Interventional

Continuous Subcutaneous Infusion of Pramlintide and Insulin

NCT00291772
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
13 Years to 22 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Not applicable Interventional Results available

Two Way Crossover Closed Loop MPC vs Control IQ

NCT05799781
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MPC closed-loop system, t:slim X2 pump with Dexcom G6 CGM and Control IQ
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 23, 2026, 7:52 AM EDT
Completed No phase listed Observational

Accuracy Characterization Study

NCT01932944
View directory record Official record
Conditions
Type2 Diabetes, Type1diabetes, Insulin Dependent Diabetes
Interventions
No treatment
Device
Lead sponsor
Abbott Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Walnut Creek, California • Rainier, Washington
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Not applicable Interventional

Cooking Matters for Diabetes - A 6-Week Program for Practical Application of Diabetes Self-Management Education

NCT04152811
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes, Type 2 Diabetes
Interventions
Cooking Matters for Diabetes, Usual Diabetes Care
Behavioral · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Continuous Glucose Sensor Profiles in Non-Diabetic Subjects

NCT00717977
View directory record Official record
Conditions
Healthy Subjects Without Type 1 Diabetes
Interventions
Continuous glucose monitor
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
8 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
10
States / cities
San Diego, California • Stanford, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Not applicable Interventional Results available

Threshold Suspend in Pediatrics at Home

NCT02120794
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
530G Insulin pump
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 15 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Phase 3 Interventional Results available

Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1

NCT00678886
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
otelixizumab infusion plus physician determined standard of care, placebo infusion plus physician determined standard of care
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
67
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 23, 2026, 7:52 AM EDT
Recruiting Phase 4 Interventional

High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy

NCT06662994
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Drug
Lead sponsor
Retina Consultants of Orange County
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Not applicable Interventional Results available

ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)

NCT03651622
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Overweight and Obesity
Interventions
Hypocaloric, low carbohydrate diet, Hypocaloric, moderate low fat diet, Mediterranean diet, no caloric restriction
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
19 Years to 30 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Palo Alto, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 23, 2026, 7:52 AM EDT
Recruiting Phase 4 Interventional

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

NCT05641753
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets, 18F-FDG, Angiocatheter 20IV, J-Wire, GlycoCheck Glycocalyx Measurement Software
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Not applicable Interventional Results available

Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver

NCT01986231
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Glucagon
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

NCT01928329
View directory record Official record
Conditions
Type I Diabetes
Interventions
Exenatide (Bydureon®), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Phase 3 Interventional Results available

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

NCT02227862
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Mylan's insulin glargine, Lantus®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
72
States / cities
Bell Gardens, California • Fresno, California • Greenbrae, California + 64 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 23, 2026, 7:52 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

NCT04101045
View directory record Official record
Conditions
Type 1 Diabetes, De Novo Lipogenesis
Interventions
Oral Glucose Tolerance Test
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
13 Years to 22 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 23, 2026, 7:52 AM EDT
No Longer Available No phase listed Expanded access

Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults

NCT03945903
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Golimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Phase 4 Interventional Results available

Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus

NCT04599075
View directory record Official record
Conditions
Type 1 Diabetes, Pregnancy, High Risk
Interventions
Insulin
Drug
Lead sponsor
Gianna Wilkie
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Oct 23, 2026, 7:52 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX

NCT03366337
View directory record Official record
Conditions
IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
Interventions
Bardoxolone methyl capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 23, 2026, 7:52 AM EDT